Boston Cambridge Biotech Networks’ Post

And we're off with a new year and here's the first #FundingFriday! Massachusetts companies brought in over $370 million in the first 9 days of 2025, including Aviceda Therapeutics $207.5M Series C to take geographic atrophy drug through phase 3 (Fierce Biotech: https://lnkd.in/eikDqZPa). And while we're on the topic of funding, congratulations to #MassBioMember Mediar Therapeutics on entering into a new partnership with Eli Lilly and Company worth $99M in upfront and near-term milestones to help fund the mid-stage idiopathic pulmonary fibrosis trial in the first six months of 2025 and bring another in-house candidate into Phase 2 in the second half of the year (Endpoints News: https://lnkd.in/ex43RF4E) #patientdriven

Longitude portfolio company Vera Therapeutics, Inc. has shown the effect of atacicept on kidney function in patients with immunoglobulin A nephropathy (IgAN) persists out to 96 weeks. The durability of the effects seen in the phase 2b trial led Evercore ISI analysts to say “this feels like a ‘functional cure’," reports Nick Paul Taylor in Fierce Biotech. Read more about atacicept's data at https://lnkd.in/eVZxWxdz #Biotech

⚡️ Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma 💊 Chroma Medicine and Nvelop Therapeutics, two biotechnology companies, have merged to form nChroma, which aims to advance research and therapy… ➡️ Read more: https://lnkd.in/ekiATKyp 🌐 Register for free focused news service covering the latest developments in relation to pharmaceutical supply: https://lnkd.in/eitNb3gD #pharma #pharmanews #APIupdates #offpatent #data #analysis #investments

Listen to Optimum Strategic Communications latest podcast around #clinicaltrials

New article published in Drug Discovery Today: Making Good Decisions in Early Drug Discovery Our team is excited to share a new article co-authored by Martin Stahl (LifeMine Therapeutics), Virginie Sandrin (Roche), and Bigna Wörsdörfer (Roche) with Ellen Coopersmith and Samuel Vardy of Decision Frameworks.  The article shares a proven and effective Decision Quality approach that guides collaborative team discussions to generate alternative discovery advancement plans and qualitatively assess them. The product is a clear decision roadmap for the team to follow and readjust as research progresses.  Read the full article here: https://lnkd.in/g_-h2gRq     #DecisionMaking #DecisionQuality #DrugDiscovery #Strategy #Uncertainty 

This is an impressive application of decision-quality principles very early in biopharma R&D.

Cystic Fibrosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Thoughts on this? >> Genetic medicine startups Chroma, Nvelop merge into nChroma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #healthcare #pharmaceutical #biotech

ICYMI, Veranova’s Senior Vice President, Chief Technology Officer, Dr. Rohtash Kumar, recently contributed to a CHEManager International article focused on the future of the CDMO industry. In the article, Dr. Kumar shares his thoughts on the redefining of drug development timelines, as well as the increased demand for complex APIs and growing emphasis on patient-centricity. He also outlines how Veranova is expanding its capabilities and embracing innovation to respond to these trends and ensure it can continue supporting the delivery of life-changing therapeutics. Read the full article to learn more: https://lnkd.in/g2dzu8BS

Bioqube Ventures is thrilled to announce the unveiling of Spica Therapeutics today, and the addition of James Rush as CEO and Jim Van heusden as Independent Chairman of the Board. With its unique macrophage fingerprinting technology, Spica is identifying and advancing innovative macrophage-subset targeted therapies that can redefine the treatment paradigm for patients across multiple disease areas. Stay tuned for the exciting progress of Spica Therapeutics via their page below! #venturecapital #lifesciences #biotech #macrophagebiology Debora Dumont Alexander Demoulin